CSBR Stock Overview
A technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Champions Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.51 |
| 52 Week High | US$7.85 |
| 52 Week Low | US$3.60 |
| Beta | 0.47 |
| 1 Month Change | 73.73% |
| 3 Month Change | 57.34% |
| 1 Year Change | 49.80% |
| 3 Year Change | -6.65% |
| 5 Year Change | -2.66% |
| Change since IPO | -37.46% |
Recent News & Updates
Sentiment Still Eluding Champions Oncology, Inc. (NASDAQ:CSBR)
Dec 10
Companies Like Champions Oncology (NASDAQ:CSBR) Can Afford To Invest In Growth
Oct 24Recent updates
Sentiment Still Eluding Champions Oncology, Inc. (NASDAQ:CSBR)
Dec 10Companies Like Champions Oncology (NASDAQ:CSBR) Can Afford To Invest In Growth
Oct 24It's A Story Of Risk Vs Reward With Champions Oncology, Inc. (NASDAQ:CSBR)
Jun 14Is Now The Time To Put Champions Oncology (NASDAQ:CSBR) On Your Watchlist?
Sep 28Champions Oncology Non-GAAP EPS of -$0.02, revenue of $12.9M
Jul 21We Think Some Shareholders May Hesitate To Increase Champions Oncology, Inc.'s (NASDAQ:CSBR) CEO Compensation
Oct 14We Think Champions Oncology (NASDAQ:CSBR) Can Afford To Drive Business Growth
Jun 21Are Investors Undervaluing Champions Oncology, Inc. (NASDAQ:CSBR) By 44%?
Apr 09Here's Why We're Not At All Concerned With Champions Oncology's (NASDAQ:CSBR) Cash Burn Situation
Mar 19The Champions Oncology (NASDAQ:CSBR) Share Price Has Gained 243%, So Why Not Pay It Some Attention?
Mar 02Is There Now An Opportunity In Champions Oncology, Inc. (NASDAQ:CSBR)?
Feb 04Do Insiders Own Lots Of Shares In Champions Oncology, Inc. (NASDAQ:CSBR)?
Jan 14Philip Breitfeld Is The Chief Strategy & Innovation Officer and Director of Champions Oncology, Inc. (NASDAQ:CSBR) And They Just Sold 100% Of Their Shares
Dec 19Champions Oncology, Inc. (NASDAQ:CSBR) Analysts Are Pretty Bullish On The Stock After Recent Results
Dec 16
Champions Oncology beats on revenue
Dec 14Estimating The Fair Value Of Champions Oncology, Inc. (NASDAQ:CSBR)
Dec 04Shareholder Returns
| CSBR | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 18.6% | -3.7% | -3.5% |
| 1Y | 49.8% | -6.6% | 22.1% |
Return vs Industry: CSBR exceeded the US Life Sciences industry which returned -6.6% over the past year.
Return vs Market: CSBR exceeded the US Market which returned 22.1% over the past year.
Price Volatility
| CSBR volatility | |
|---|---|
| CSBR Average Weekly Movement | 11.6% |
| Life Sciences Industry Average Movement | 9.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CSBR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CSBR's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 210 | Ronnie Morris | www.championsoncology.com |
Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process.
Champions Oncology, Inc. Fundamentals Summary
| CSBR fundamental statistics | |
|---|---|
| Market cap | US$103.43m |
| Earnings (TTM) | -US$598.00k |
| Revenue (TTM) | US$53.57m |
1.9x
P/S Ratio-171.9x
P/E RatioIs CSBR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CSBR income statement (TTM) | |
|---|---|
| Revenue | US$53.57m |
| Cost of Revenue | US$29.60m |
| Gross Profit | US$23.97m |
| Other Expenses | US$24.57m |
| Earnings | -US$598.00k |
Last Reported Earnings
Oct 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.044 |
| Gross Margin | 44.75% |
| Net Profit Margin | -1.12% |
| Debt/Equity Ratio | 0% |
How did CSBR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 23:00 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/10/31 |
| Annual Earnings | 2024/04/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Champions Oncology, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Paul Bienstock | B. Riley Wealth |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| Paul Knight | Janney Montgomery Scott LLC |